Stereotaxis Stock News

ST. LOUIS, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r

ST. LOUIS, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r

Stereotaxis, Inc. (NYSE:STXS ) Q2 2022 Earnings Conference Call August 9, 2022 10:00 AM ET Company Representatives David Fischel - Chairman, Chief Executive Officer Kim Peery - Chief Financial Officer

ST. LOUIS, July 19, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r

Stereotaxis, Inc. (NYSE:STXS ) Q1 2022 Earnings Conference Call May 10, 2022 10:00 AM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Parti

Solid Q4 beat overshadowed by prudent guidance that removes 4 "imminent" replacement system sales from FY2022 outlook. As per quarterly call, all have physician/administration support and remain “im

Stereotaxis, Inc.'s (STXS) CEO David Fischel on Q4 2021 Results - Earnings Call Transcript

Stereotaxis press release (STXS): Q4 GAAP EPS of -$0.05 misses by $0.01.Revenue of $8.2M (+20.2% Y/Y) beats by $0.54M.

ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Stereotaxis (NYSE:STXS) is scheduled to announce Q4 earnings results on Thursday, March 3rd, before market open.The consensus EPS Estimate is -$0.04 and the consensus Revenue Estimate…

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, chairman and CEO, will present at three investor conferences in the first quarter 2022.

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis

ST. LOUIS, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r

"Stereotaxis reminds me in many ways of Intuitive Surgical in our early years." - Executive VP & CMO of Intuitive Surgical and new Stereotaxis board member. Innovation Day showcased significant cataly